Mesoblast Shares Dip Despite Strong Ryoncil Sales as Market Prices in Growth

Mesoblast Ltd (MSB) reported robust quarterly performance for its flagship product, Ryoncil, which generated US$30.3 million in sales during the March quarter. This milestone brings the cumulative sales for the treatment to nearly US$100 million since its initial launch. Despite these strong fundamental results, the company's share price experienced a decline during recent trading sessions after previously hitting a 52-week high. Analysts suggest that the positive sales data had already been factored into the stock price, leading to a "sell the news" reaction among investors. Market participants are now shifting their attention toward long-term revenue guidance for FY2026 and the sustainability of profit margins. This price action underscores a cautious sentiment in the biotech sector as traders look for new catalysts beyond current earnings data.